Anterior Approach for Hepatectomy Before Piggyback Liver Transplantation in Giant Polycystic Liver Disease
Daniela Kniepeiss, Philipp Stiegler, Emina Talakic, Peter Schemmer – 19 June 2020
Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co‐Metabolism in Patients With Alcoholic Hepatitis
Bei Gao, Yi Duan, Sonja Lang, Dinesh Barupal, Tsung‐Chin Wu, Luis Valdiviez, Bryan Roberts, Ying Yng Choy, Tong Shen, Gregory Byram, Ying Zhang, Sili Fan, Benjamin Wancewicz, Yan Shao, Kevin Vervier, Yanhan Wang, Rongrong Zhou, Lu Jiang, Shilpa Nath, Rohit Loomba, Juan G. Abraldes, Ramon Bataller, Xin M. Tu, Peter Stärkel, Trevor D. Lawley, Oliver Fiehn, Bernd Schnabl – 19 June 2020 – Alcohol‐related liver disease is a major public health burden, and the gut microbiota is an important contributor to disease pathogenesis.
Expanding Blood Type A2‐to‐B Liver Transplantation: An Alternative for High Model for End‐Stage Liver Disease Score Patients
James B. Hendele, James D. Perkins, Lena Sibulesky – 18 June 2020
Local and Regional Therapies for Hepatocellular Carcinoma
Roman Kloeckner, Peter Robert Galle, Jordi Bruix – 18 June 2020
Liver X Receptor Alpha Activation Inhibits Autophagy and Lipophagy in Hepatocytes by Dysregulating Autophagy‐Related 4B Cysteine Peptidase and Rab‐8B, Reducing Mitochondrial Fuel Oxidation
Yun Seok Kim, Hyeon Joo Nam, Chang Yeob Han, Min Sung Joo, Kiseok Jang, Dae Won Jun, Sang Geon Kim – 17 June 2020
Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage
Mark W. Russo, Oren K. Fix, Ayman A. Koteish, Katie Duggan, Marcia Ditmyer, Michael Fuchs, Raymond T. Chung, Gautham Reddy – 17 June 2020
APECED‐Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort
David M. Chascsa, Elise M. N. Ferré, Yannis Hadjiyannis, Hawwa Alao, Mukil Natarajan, Mariam Quinones, David E. Kleiner, Thomas L. Simcox, Ehsan Chitsaz, Stacey R. Rose, Asa Hallgren, Olle Kampe, Jamie Marko, Rabab O. Ali, Sungyoung Auh, Christopher Koh, Yasmine Belkaid, Michail S. Lionakis, Theo Heller – 17 June 2020
Diagnostic and Prognostic Significance of Complement in Patients With Alcohol‐Associated Hepatitis
Xiude Fan, Rebecca L. McCullough, Emily Huang, Annette Bellar, Adam Kim, Kyle L. Poulsen, Craig J. McClain, Mack Mitchell, Arthur J. McCullough, Svetlana Radaeva, Bruce Barton, Gyongyi Szabo, Srinivasan Dasarathy, Daniel M. Rotroff, Laura E. Nagy – 17 June 2020
Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim – 16 June 2020 – Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared.
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Zobair M. Younossi, Mary E. Rinella, Arun J. Sanyal, Stephen A. Harrison, Elizabeth M. Brunt, Zachary Goodman, David E. Cohen, Rohit Loomba – 16 June 2020 – Despite the substantial gains in our understanding of NAFLD/NASH over the past 2 decades, there has been some dissatisfaction with the terminology “non‐alcoholic” which overemphasizes “alcohol” and underemphasizes the root cause of this liver disease, namely, the predisposing metabolic risk factors. As a potential remedy, a name change from NAFLD to metabolic associated fatty liver disease (MAFLD) has been proposed.